Table 1.
Demographics
| Total transition visits (N = 19) n (%) or mean (range) | |
|---|---|
| Telemedicine equipment usage | |
| As planned (TLMD-STD) | 13 (68.4) |
| Audio without video (TLMD-MOD) | 1 (5.3) |
| Phone conference call (TLMD-MOD) | 5 (26.3) |
| Survivor demographics | |
| Sex (Female) | 14 (73.7) |
| Race (Caucasian) | 18 (94.7) |
| Age (years) | 26.52 (21–41) |
| Age at cancer diagnosis (years) | 7.8 (1–15) |
| Time since completion of therapy (years) | 16.84 (10–28) |
| Cancer diagnosis | |
| Acute lymhoblastic leukemia | 6 (31.6) |
| Acute myelocytic leukemia | 3 (15.8) |
| Hodgkin's lymohoma | 3 (15.8) |
| Wilm's tumor | 2 (10.5) |
| Osteosarcoma | 1 (5.3) |
| Ewing's sarcoma | 1 (5.3) |
| Medulloblastoma | 1 (5.3) |
| Treatments received | |
| Chemotherapy (yes) | 19 (100) |
| Radiation (yes) | 8 (42.1) |
| Oncologic Surgery (yes) | 4 (21.1) |
| Hematopoietic stem cell transplant (yes) | 3 (15.8) |
| Intensity of treatment | |
| Level 1 | 2 (10.5) |
| Level 2 | 6 (31.6) |
| Level 3 | 6 (31.6) |
| Level 4 | 5 (26.3) |
TLMD-MOD, telemedicine modified; TLMD-STD, telemedicine standard.